摘要
目的:观察环氧化酶-2(COX-2)抑制剂塞来昔布联合多西他赛加顺铂(DP方案)一线治疗晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法:46例晚期NSCLC患者随机分为观察组24例和对照组22例,2组均接受相同的DP方案化疗,观察组化疗前5d开始予塞来昔布400mg,口服,2次/d,3周为1个周期。结果:第4～6个周期化疗结束后,观察组与对照组有效率分别为45.8%(11/24)和31.8%(7/22),但差异无统计学意义,P=0.331。疾病控制率分别为83.3%(20/24)和54.5%(12/22),1年生存率分别为66.7%(16/24)和36.4%(8/22),差异有统计学意义,P值分别为0.034和0.04。两组毒副作用主要为乏力、胃肠道反应和骨髓抑制,差异无统计学意义,P值分别为0.947、0.99和0.811。结论:塞来昔布联合DP方案一线治疗晚期NSCLC可提高临床疗效,不增加不良反应,是一种有效安全的治疗方法。
OBJECTIVE： To investigate the efficacy and safety of COX-2 inhibitor （celecoxib） with docetaxel plus cisplatin （DP） in the first-line treatment of non-small cell lung cancer （NSCLC）. METHODS： Forty-six patients with NSCLC were randomly assigned to the observeation group （24 cases） and controll group（22 cases）. Both groups received DP regimen and one of them with celecoxib 400 mg twice daily, 5 days before chemotherapy for 3 weeks and another group without. RESULTS： Four to 6 cycles later, compared with the controlled group, the response rate （RR） in obseration group was 45.8%（11/24） vs 31. 8%（7/22,P=0. 331）,disease controll rate （DCR） was 83. 3%（20/24） vs 54. 5% （12/22,P=0. 034） ,one-year survival rate was 66.7% （16/24） vs 36.4%（8/22,P=0.04）. The main toxicities in the two groups were nausea, vomitting and myelosuppresion （P = 0.947 ; P = 0.99 ; P = 0.811 ）. CONCLUSION ： Compared with DP alone,celecoxib combined with DP are able to improve theraputic efficacy without the increasing of toxicities.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2012年第21期1661-1663,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
苏州市科教兴卫青年专项基金(SWQ22)
关键词
药物疗法
联合
癌
非小细胞肺
治疗效果
drug therapy,combination
carcinoma, non-small cell lung
treatment outcome
